Almaden Genomics is accelerating drug discovery with g.nome™, a cloud-native platform designed to unite scientists and bioinformaticians in high-throughput sequencing data analysis. Brought to market by a team of bioinformaticians, engineers and industry professionals, g.nome provides an easy-to-use GUI workflow builder with strong iteration, version control and data provenance capabilities, and enables bioinformaticians and biologists to collaborate more effectively by translating complex code into easy-to-understand, visual representations. Formerly part of IBM Research, Almaden Genomics became a new standalone company under Catalyze Dallas' ownership in 2022.